Jenburkt Pharmaceuticals Ltd - Research Report


Private Client Research




Pharmaceuticals & Drugs


Jenburkt Pharmaceuticals Ltd

Reco Price
Rs. 477.00
Price Target (1.5 - 2 Years)
Rs. 952.00


June 08, 2017
CNX Nifty




Strengthening the company’s brands will drive future growth.

Strong Domestic Operations:
Jenburkt Pharma Ltd., engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products, has a strong committed sales force team spread across India. Jenburkt promotes all its 85 brands ethically across 75,000 doctors and 50,000 chemists regularly. Backing the strong sales force, the company has more than 1,000 stockists and 25 super-stockists. Jenburkt also caters to large Government and Semi-Government Institutions, Missionary Hospitals, Public Sector Enterprises, etc.

Strengthening the Company’s Brands:
There is a growing trend of competition from regional companies who operate either in a few districts or in a few states in India. This is apart from the competition from large organizations operating in India. In order to tackle competition, during the previous year, the company focussed on strengthening its brands in their respective segments. Additionally, neuropathy detection camps and bone densitometry camps were carried out in various parts of the country for detection of neuropathy and osteoporosis. The strategy of the company is to focus on long term therapies in acute and chronic ailments by moving up the value chain continuously. As a result, a few of the company’s brands are the preferred choice in certain segments. The company has some strong brands including CARTI SAFE FORTE (Anti Arthritic), POWERGESIC Tablets (Anti Inflammatory Analgesic). It ranks among the top five in these segments.

Quality Products’ Portfolio:
Jenburkt has a strong portfolio of quality products that include prescription and over-the-counter drugs. The company’s prescription medicines span across various therapeutic areas such as anti-arthritic, anti-malarials, anti-osteoporotic, antibiotics, anti-diabetics, anti-inflammatory drugs and more.

Strong Manufacturing Facilities:
Jenburkt has strong manufacturing facilities to cater to both the domestic and international markets. The company has a state-of-the-art manufacturing plant at Sihor-Gujarat in India. The plant is modern and well-equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products. The company’s plant is approved as per W.H.O. (World Health Organization) guidelines and has approvals from various countries. Furthering the development of formulations, Jenburkt has a Research & Development unit duly approved by the Ministry of Science & Technology, Government of India. Jenburkt also manufactures high quality formulations backed by strong Research & Development which adheres to regulations and is marketed by its global marketing team. Jenburkt's strategy is to focus on creating a new category in the Indian and the International pharmaceutical market.

Strong R&D Activities:
Through Research & Development, the company is in the continuous process of improving on its product portfolio. Recently, the company undertook commercial scale manufacturing of Frendacid, an antacid and anti-flatulence drug for the export market. The company also continues to work towards formulating new and existing molecules for the domestic and international markets for efficient and cost saving drug delivery systems.

Growing Export Market:
Currently, Jenburkt's products are being exported to 15 countries globally with a clear focus to expand on a yearly basis. The company is also scouting for a capable partner to market its pharmaceutical products across the globe in order to increase its export sales which presently constitutes a modest proportion of total sales. Also Jenburkt is open to partnering with foreign pharmaceutical firms to market their pharmaceutical products in India.

Resolved export oriented issues:
The company’s export sales presently contribute 14% of the total sales. Jenburkt faced some challenges with some of its export markets, particularly Sri Lanka, which contributes to around 6% of sales where a leading distributor in the country was facing financial instability and top management attrition. To overcome this issue, Jenburkt appointed a new distributor which impacted 4 months of sales thereby affecting its lucrative export business margins.

Apart from Sri Lanka, the company faced challenges in Benin (Africa) too where due to political uncertainty, distributors were not accepting orders. However, these issues have been resolved and exports have resumed.

Stock Data

CMP (Rs)
Face value (Rs)
52 Week Range (Rs)
572.50 - 340.10
Market cap (Rs Crores)
Price To Book Value (x)
P/E Ratio (x)

One Year indexed Stock Performance

Jenburkt Pharmaceuticals LtdSensex
Jenburkt Pharmaceuticals Ltd
Return (%)


(in %)

+91 22 6639 3000



The Indian pharmaceutical industry is poised to escalate its growth mainly due to the potentially huge demand for innovative and world class quality drugs in India and in the overseas market; however, pricing plays a vital role for companies in the industry. The growth in the industry is mainly driven by contract manufacturing and backward integration, resulting in quality control and reduction in cost.

The industry is highly fragmented and spread across the country. It can be broadly categorized into the organised and the unorganised segments. SMEs are at the core of the growth of the industry. SMEs are taking advantage of the demand of high quality products in India and in the global market and new markets opening with respect to clinical trials and innovations.

About the Company

Jenburkt Pharmaceuticals Ltd, a player in the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta. Headquartered in Mumbai, Jenburkt is engaged in the manufacture and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company with its stock listed on the Bombay Stock Exchange.

Profit & Loss Statement:- (Standalone)
(Rs Crores)
  • Net Sales
  • Growth (%)
  • Total Expenditure
  • % Margin
  • Other Income
  • Operating Profit
  • Interest
  • PBDT
  • Depreciation
  • Profit Before Taxation & Exceptional Items
  • Exceptional Income / Expenses
  • Tax
  • Profit After Tax
  • Adjusted EPS
  • 76.22
  • -
  • 64.71
  • 11.52
  • 15.11
  • 1.61
  • 13.13
  • 1.27
  • 11.86
  • 1.55
  • 10.31
  • 0.02
  • 2.82
  • 7.51
  • 16.15
  • 85.21
  • 11.79
  • 69.96
  • 15.25
  • 17.90
  • 2.07
  • 17.33
  • 0.36
  • 16.97
  • 2.66
  • 14.31
  • 0.03
  • 4.69
  • 9.65
  • 20.75
  • 93.59
  • 9.83
  • 77.13
  • 16.46
  • 17.59
  • 2.73
  • 19.19
  • 0.38
  • 18.81
  • 1.99
  • 16.82
  • 0.01
  • 6.05
  • 10.78
  • 23.18
  • 103.31
  • 10.39
  • 83.57
  • 19.74
  • 19.11
  • 2.76
  • 22.50
  • 0.41
  • 22.09
  • 1.79
  • 20.30
  • 0.13
  • 6.97
  • 13.46
  • 28.96
  • 118.81
  • 15.00
  • 95.05
  • 23.76
  • 20.00
  • 2.75
  • 26.51
  • 0.40
  • 26.11
  • 1.75
  • 24.36
  • 0.00
  • 8.53
  • 15.83
  • 34.07
  • 136.63
  • 15.00
  • 109.30
  • 27.33
  • 20.00
  • 2.75
  • 30.08
  • 0.39
  • 29.69
  • 1.70
  • 27.99
  • 0.00
  • 9.79
  • 18.19
  • 39.14
Source: Stockaxis Research, Company Data


The company's strong product portfolio and deeper penetration in international market will lead to next phase of growth.

We Initiate ‘BUY’ on attractive valuations with Target Price of Rs 952 based on 24.32x FY19E EPS. The stock trades at 14.00x FY18E and 12.20x FY19E EPS.



Opulent Investment Adviser Private Limited is registered as an Investment Adviser with SEBI bearing registration Number INA000002462 as per Securities and Exchange Board of India (Investment Advisers) Regulations, 2013. Opulent Investment Adviser Private Limited offer investment advisory services to clients as well as prospects.

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Opulent Investment Adviser Private Limited and its Research Analyst with reference to the subject company(s) covered in this report-:

Opulent Investment Adviser Private Limited does have any financial interest in the subject company: (NO)

Research Analyst or his/her relative’s have financial interest in the subject company: (NO)

Opulent Investment Adviser Private Limited and Research Analyst or his/her relative’s does have any material conflict of interest in the subject company: (NO)

Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: (NO)

The research Analyst has served as officer, director or employee of the subject company: (NO)

Our salespeople and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein.

This report is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person.

This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of the users of / Opulent Investment Adviser Private Limited.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and we do not warrant its accuracy or completeness.

Opulent Investment Adviser Private Limited, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report.